 |
 Video: What is a Stock Split?
|
|
|
| Taysha Gene Therapies is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. Together with The University of Texas Southwestern Medical Center, Co. has a portfolio of gene therapy product candidates. Co.'s portfolio of gene therapy candidates targets neurological indications across three therapeutic categories: neurodegenerative diseases, neurodevelopmental disorders and genetic epilepsies. Co. owns worldwide rights to a clinical-stage intrathecally dosed AAV9 gene therapy program for the treatment of giant axonal neuropathy. According to our Taysha Gene Therapies stock split history records, Taysha Gene Therapies has had 0 splits. | |
|
Taysha Gene Therapies (TSHA) has 0 splits in our Taysha Gene Therapies stock split history database.
Looking at the Taysha Gene Therapies stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Taysha Gene Therapies shares, starting with a $10,000 purchase of TSHA, presented on a split-history-adjusted basis factoring in the complete Taysha Gene Therapies stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
09/25/2020 |
|
| End date: |
04/29/2024 |
|
| Start price/share: |
$24.47 |
|
| End price/share: |
$2.45 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-89.99% |
|
| Average Annual Total Return: |
-47.28% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,001.46 |
|
| Years: |
3.59 |
|
|
|
|
|
